StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) stock

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.60−0.03 (-4.75%)

Close on Nov 18, 2026Market cap $57.06MP/E –Yield –

Cognition Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cognition Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$36.60M. For fiscal 2025 it was -$47.80M. The highest annual figure on record is -$17.41M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$47.80M–
FY2024Dec 31, 2024-$53.97M–
FY2023Dec 31, 2023-$50.72M–
FY2022Dec 31, 2022-$43.55M–
FY2021Dec 31, 2021-$28.60M–
FY2020Dec 31, 2020-$17.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.74M–
Q1 FY2026Mar 31, 2026-$8.82M–
Q4 FY2025Dec 31, 2025-$13.67M–
Q3 FY2025Sep 30, 2025-$6.38M–
Q2 FY2025Jun 30, 2025-$13.98M–
Q1 FY2025Mar 31, 2025-$13.78M–
Q4 FY2024Dec 31, 2024-$10.72M–
Q3 FY2024Sep 30, 2024-$14.46M–
Q2 FY2024Jun 30, 2024-$14.68M–
Q1 FY2024Mar 31, 2024-$14.10M–
Q4 FY2023Dec 31, 2023-$15.19M–
Q3 FY2023Sep 30, 2023-$14.75M–
Q2 FY2023Jun 30, 2023-$11.82M–
Q1 FY2023Mar 31, 2023-$8.97M–
Q4 FY2022Dec 31, 2022-$9.30M–
Q3 FY2022Sep 30, 2022-$12.63M–
Q2 FY2022Jun 30, 2022-$12.21M–
Q1 FY2022Mar 31, 2022-$9.41M–
Q4 FY2021Dec 31, 2021-$11.81M–
Q3 FY2021Sep 30, 2021-$5.22M–
Q2 FY2021Jun 30, 2021-$5.98M–
Q1 FY2021Mar 31, 2021-$5.58M–
Q4 FY2020Dec 31, 2020-$4.12M–
Q3 FY2020Sep 30, 2020-$4.46M–

More Cognition Therapeutics figures

See a number that looks wrong?